Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

'Supportive' brain cells may actively drive cognitive decline

Brain cells that produce the protective coating around nerve fibers can become dysfunctional with age and may actively contribute to cognitive decline, according to new research.

'Supportive' brain cells may actively drive cognitive decline

Research reveals that brain cells responsible for producing the protective myelin coating around nerve fibers may actively contribute to cognitive decline as people age. A study published in Nature Medicine found that individuals with more severe cognitive decline exhibited alterations in nerve fibers and myelin compared to those with milder decline.

Experiments on mice demonstrated that disrupting oligodendrocytes, the cells that produce myelin, also impacted the coating and cognitive performance. This discovery, which contradicts the previous belief that these cells are always supportive, may lead to novel treatments targeting oligodendrocyte dysfunction to preserve cognition in later life.

The research was based on brain tissue analysis from the Lothian Birth Cohort 1936, a group of individuals assessed for cognitive abilities from childhood into older age, with follow-up cognitive testing conducted for 866 participants after age 70. Further analysis of postmortem brain tissue revealed that severe cognitive decline was linked to fewer large nerve fibers, excess unhealthy myelin, and reduced levels of the NRF2 protein in oligodendrocytes.

NRF2 regulates numerous genes involved in cell protection and healthy function. Mice experiments showed that reduced NRF2 activity in oligodendrocytes led to excess myelin, fewer large nerve fibers, and impaired cognitive performance. The findings suggest that NRF2 activity reduction can drive oligodendrocyte dysfunction, contributing to cognitive decline associated with aging.

The NRF2 pathway is already targeted by drugs, including one used to treat multiple sclerosis, suggesting potential repurposing for cognitive decline treatments.

Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at medicalxpress.com →

More in Health & Medicine

Celltrion, Samsung Bioepis Battle Over Keytruda Biosimilar

As the patent expiration of the global top-selling mega blockbuster drug ‘Keytruda (ingredient name pembrolizumab)’ approaches, South Korea’s two biotechnology giants, Celltrion and Samsung Bioepis…

  • Celltrion leads biosimilar race with CT-P51, approved via fast-track
  • Samsung Bioepis counters with SB27, backed by phase 3 data from 600+ patients
  • Patent expiry in September creates crucial market battleground

More from Tuesday 25 August →